1. Home
  2. TEI vs RIGL Comparison

TEI vs RIGL Comparison

Compare TEI & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TEI
  • RIGL
  • Stock Information
  • Founded
  • TEI 1993
  • RIGL 1996
  • Country
  • TEI United States
  • RIGL United States
  • Employees
  • TEI N/A
  • RIGL N/A
  • Industry
  • TEI Finance Companies
  • RIGL Biotechnology: Pharmaceutical Preparations
  • Sector
  • TEI Finance
  • RIGL Health Care
  • Exchange
  • TEI Nasdaq
  • RIGL Nasdaq
  • Market Cap
  • TEI 262.1M
  • RIGL 486.4M
  • IPO Year
  • TEI N/A
  • RIGL 2000
  • Fundamental
  • Price
  • TEI $5.20
  • RIGL $17.09
  • Analyst Decision
  • TEI
  • RIGL Buy
  • Analyst Count
  • TEI 0
  • RIGL 5
  • Target Price
  • TEI N/A
  • RIGL $34.80
  • AVG Volume (30 Days)
  • TEI 142.4K
  • RIGL 203.8K
  • Earning Date
  • TEI 01-01-0001
  • RIGL 11-07-2024
  • Dividend Yield
  • TEI 10.51%
  • RIGL N/A
  • EPS Growth
  • TEI N/A
  • RIGL N/A
  • EPS
  • TEI N/A
  • RIGL 0.22
  • Revenue
  • TEI N/A
  • RIGL $157,374,000.00
  • Revenue This Year
  • TEI N/A
  • RIGL $48.98
  • Revenue Next Year
  • TEI N/A
  • RIGL $14.43
  • P/E Ratio
  • TEI N/A
  • RIGL $77.18
  • Revenue Growth
  • TEI N/A
  • RIGL 21.65
  • 52 Week Low
  • TEI $4.35
  • RIGL $7.48
  • 52 Week High
  • TEI $5.39
  • RIGL $29.82
  • Technical
  • Relative Strength Index (RSI)
  • TEI 37.23
  • RIGL 30.82
  • Support Level
  • TEI $5.10
  • RIGL $16.68
  • Resistance Level
  • TEI $5.27
  • RIGL $19.80
  • Average True Range (ATR)
  • TEI 0.07
  • RIGL 1.53
  • MACD
  • TEI -0.02
  • RIGL -1.05
  • Stochastic Oscillator
  • TEI 31.43
  • RIGL 3.66

About TEI Templeton Emerging Markets Income Fund Inc.

Templeton Emerging Markets Income Fund is a closed-end fund. It seeks high, current income, with a secondary goal of capital appreciation, by investing, under normal market conditions. The company's investment portfolio includes Foreign Government and Agency Securities; Quasi-Sovereign and Corporate Bonds; Common Stocks and Other Equity Interests, and Short-Term Investments and Money Market Funds.

About RIGL Rigel Pharmaceuticals Inc.

Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's lead drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.

Share on Social Networks: